NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Edesa Biotech, Inc. EDSA
13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-7.2M
Growth
—
Revenue, FY2025 · full 13-year series below
Revenue $M
Net income $M
FY2021 · Revenue 0.0 · Net income -13.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2020 · Operating -1946.7% · Net -1935.3%
ROE
FY2025 · ROE -99.6%
Each USD of equity lost 100 cents this year.
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | 7.0 | 8.3 | 9.6 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | · | · | −1.10 | −0.74 | −1.76 | −3.44 | −0.57 | −0.36 | −1.11 | −2.81 | −0.13 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −99.6 | −136.7 | −101.9 | −156.3 | −135.5 | −96.0 | −53.9 | −51.0 | −49.5 | −36.2 | −306.6 | · | −612.9 |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.06 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 37 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2012